IVSI - ETF AI Analysis

Top Page

Applied Finance IVS International Large ETF (IVSI)

Rating:67Neutral

Price Target:―

IVSI, the Applied Finance IVS International Large ETF, has a solid overall rating driven mainly by high-quality global leaders like ASML, AstraZeneca, and Novartis, which show strong financial performance, positive earnings sentiment, and generally supportive technical trends. These strengths are partly offset by holdings such as Deutsche Telekom, Unilever, and BHP, where bearish or mixed technical signals and some valuation concerns weigh on the fund. The main risk factor is that several key positions show signs of being overvalued or technically weak in the short term, which could add volatility even though the underlying businesses are strong.

Positive Factors

Strong Recent Performance

The ETF has shown positive returns so far this year and over the past month, indicating recent upward momentum.

Leading Global Companies in Top Holdings

Several of the largest positions, such as ASML and major healthcare names, have delivered strong gains, helping support the fund’s overall results.

Broad International and Sector Diversification

Holdings spread across many countries and sectors, with meaningful exposure to financials, health care, industrials, and technology, help reduce reliance on any single market or industry.

Negative Factors

Relatively High Expense Ratio

The fund’s fee is on the higher side for an ETF, which can gradually eat into investor returns over time.

Small Asset Base

With a relatively low level of assets under management, the ETF may face higher trading spreads and a greater risk of closure compared with larger funds.

Some Top Holdings Are Lagging

A few notable positions, such as LVMH and Unilever, have shown weak or negative performance this year, which can drag on the fund’s overall progress.

IVSI vs. SPDR S&P 500 ETF (SPY)

AUM7.70M

RegionDeveloped Markets

Expense Ratio0.65%

Beta0.16

IssuerApplied Finance

Inception DateDec 11, 2025

Dividend Yield0.04%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume2,478

30 Day Avg. Volume6,387

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

29.75

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering187

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

IVSI Summary

The Applied Finance IVS International Large ETF (IVSI) is an actively managed fund that invests in large, well-established companies outside the U.S., mainly in countries like Japan, the UK, France, and Switzerland. It doesn’t track a set index, but instead picks stocks based on the manager’s research. The fund holds well-known names such as ASML, Roche, AstraZeneca, Novartis, and LVMH, and spreads money across many sectors, which can help with global diversification and long-term growth potential. A key risk is that international stocks can go up and down with global markets and currency swings.

How much will it cost me?This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, with managers doing in-depth research to pick international large-cap stocks rather than just tracking an index.

What would affect this ETF?This ETF could benefit if developed markets outside North America grow steadily, especially if demand stays strong for global health care, financial, and technology leaders like ASML, Roche, and AstraZeneca, and if a weaker U.S. dollar makes international stocks more attractive. On the other hand, it could face challenges from slower economic growth in Europe or Japan, tighter global financial conditions, changing regulations affecting banks and drug makers, or a downturn in commodity and luxury goods demand that would hurt holdings like Rio Tinto and LVMH.

IVSI Top 10 Holdings

IVSI leans heavily on a trio of European pharma giants—Roche, AstraZeneca, and Novartis—which have been steadily rising and act as the fund’s defensive engine. ASML is the high-octane growth name, helping drive performance as chip demand stays strong. On the value side, Mitsubishi UFJ and miners like Rio Tinto and BHP are climbing, giving the fund a cyclical kicker. L’Oreal, by contrast, has been losing a bit of shine lately, slightly tugging on returns. Overall, it’s a developed-markets ex-U.S. mix with a tilt toward health care and select global champions.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
ASML	ASML Holding NV	6.24%	$480.87K	€475.49B	74.46%	76 Outperform
ROG	Roche Holding AG	4.27%	$329.05K	CHF294.84B	46.01%	73 Outperform
AZN	AstraZeneca	3.35%	$258.03K	$323.92B	30.42%	80 Outperform
NOVN	Novartis AG	2.96%	$227.86K	CHF242.43B	28.84%	80 Outperform
DTE	Deutsche Telekom	2.55%	$196.42K	€158.31B	-5.01%	67 Neutral
8306	Mitsubishi UFJ Financial Group	1.93%	$148.97K	¥33.00T	48.01%	76 Outperform
RIO	Rio Tinto Limited	1.85%	$142.59K	AU$238.88B	46.67%	78 Outperform
ULVR	Unilever	1.73%	$133.09K	£116.19B	8.76%	72 Outperform
OR	L'Oreal	1.73%	$132.95K	€210.07B	17.03%	71 Outperform
BHP	BHP Group Ltd	1.72%	$132.20K	AU$265.54B	50.41%	68 Neutral

IVSI Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

100DMA

200DMA

Market Momentum

MACD

0.51

Negative

RSI

73.45

Negative

STOCH

91.51

Negative

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IVSI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 27.50, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.51 indicates Negative momentum. The RSI at 73.45 is Negative, neither overbought nor oversold. The STOCH value of 91.51 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IVSI.

IVSI Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
IVSI	―	―	$7.70M	0.65%	67 Neutral
JIRE	―	―	$10.35B	0.24%	67 Neutral
QUIZ	―	―	$69.66M	0.56%	66 Neutral
AIVI	―	―	$63.17M	0.58%	62 Neutral
TACN	―	―	$19.47M	0.00%	66 Neutral
PQNT	―	―	$10.07M	0.30%	67 Neutral

Performance Comparison

IVSI

Applied Finance IVS International Large ETF

28.23

2.89

11.40%

JIRE

JPMorgan International Research Enhanced Equity ETF

―

QUIZ

Zacks Quality International ETF

―

AIVI

WisdomTree International AI Enhanced Value Fund

―

TACN

T. Rowe Price Active Core International Equity ETF

―

PQNT

Pictet AI Enhanced International Equity ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents